derm aid 05 cream - otsingu tulemused

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiidi ained, välja arvatud kortikosteroidid - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Eesti - eesti - Ravimiamet

matrifen transdermaalne plaaster

takeda pharma as - fentanüül - transdermaalne plaaster - 25mcg 1h 3tk; 25mcg 1h 4tk; 25mcg 1h 8tk; 25mcg 1h 5tk; 25mcg 1h 16tk; 25mcg 1h 1tk; 25mcg 1h 2tk; 25mcg 1h 20tk; 25mcg 1h 10tk

Eesti - eesti - Ravimiamet

opiodur 75mcg/h transdermaalne plaaster

pharmabide ltd. - fentanüül - transdermaalne plaaster - 75mcg 1h 5tk; 75mcg 1h 10tk; 75mcg 1h 20tk; 75mcg 1h 3tk; 75mcg 1h 16tk

Eesti - eesti - Ravimiamet

norspan transdermaalne plaaster

mundipharma ges.m.b.h. - buprenorfiin - transdermaalne plaaster - 20mcg 1h 10tk; 20mcg 1h 8tk; 20mcg 1h 5tk; 20mcg 1h 4tk; 20mcg 1h 12tk; 20mcg 1h 2tk; 20mcg 1h 3tk; 20mcg 1h 1tk